Clinical trial
A Phase III b, Multicenter Study of the Efficacy and Safety of Aflibercept Switch in Patients With Exudative AMD With Detachment of the Retinal Pigment Epithelium and Previously Treated With Ranibizumab Intravitreal Injection. (ARI2)
NCT02157077 is registered in ClinicalTrials.gov with Centre Hospitalier Intercommunal Creteil as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III b, Multicenter Study of the Efficacy and Safety of Aflibercept Switch in Patients With Exudative AMD With Detachment of the Retinal Pigment Epithelium and Previously Treated With Ranibizumab Intravitreal Injection. (ARI2)
- Lead sponsor
- Centre Hospitalier Intercommunal Creteil
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2013
- Completion date
- December 31, 2015
- Enrollment
- 84 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.